论文部分内容阅读
肿瘤治疗中单独或联合应用IL-2和TNFα的效果并不理想,可能与肿瘤及其周围组织中单核巨噬细胞产生的反应性氧代谢物有关,消除这些物质或抑制其生成,理论上应能提高IL-2的抗肿瘤活性。组胺在无单核巨噬细胞存在时不影响T/NK细胞的抗肿瘤活性,有单核巨噬细胞时能有效抑制其中反应性氧代谢物的产生,是IL-2治疗的理想佐剂。体外试验证明,联合应用IL-2和组胺的抗肿瘤作用是肯定的。临床试验治疗急性髓系白血病(AML)和多发性骨髓瘤(MM)也取得了一定的疗效,但病例数较少,其结论尚需大样本、多中心及随机对照试验验证。
The effects of using IL-2 and TNFα, either alone or in combination, in tumor therapy are not ideal and may be related to reactive oxygen metabolites produced by mononuclear macrophages in the tumor and its surrounding tissues, eliminating these substances or inhibiting their production. Theoretically It should increase the antitumor activity of IL-2. Histamine does not affect the anti-tumor activity of T/NK cells in the presence of mononuclear macrophages, and can effectively inhibit the production of reactive oxygen metabolites in mononuclear macrophages, making it an ideal adjuvant for IL-2 therapy. . In vitro tests have shown that the combined anti-tumor effect of IL-2 and histamine is positive. Clinical trials have also achieved certain efficacy in the treatment of acute myeloid leukemia (AML) and multiple myeloma (MM), but the number of cases is small. The conclusions need to be verified by large samples, multiple centers, and randomized controlled trials.